A detailed history of Charles Schwab Investment Management Inc transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 465,620 shares of AGIO stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
465,620
Previous 457,527 1.77%
Holding current value
$16.5 Million
Previous $19.7 Million 4.86%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$41.19 - $49.72 $333,350 - $402,383
8,093 Added 1.77%
465,620 $20.7 Million
Q2 2024

Aug 12, 2024

BUY
$27.55 - $48.83 $476,477 - $844,514
17,295 Added 3.93%
457,527 $19.7 Million
Q1 2024

May 08, 2024

SELL
$21.32 - $34.81 $344,573 - $562,599
-16,162 Reduced 3.54%
440,232 $12.9 Million
Q4 2023

Feb 06, 2024

BUY
$19.97 - $24.53 $93,839 - $115,266
4,699 Added 1.04%
456,394 $10.2 Million
Q3 2023

Nov 08, 2023

BUY
$24.36 - $28.18 $351,271 - $406,355
14,420 Added 3.3%
451,695 $11.2 Million
Q2 2023

Aug 09, 2023

BUY
$21.38 - $29.19 $159,558 - $217,844
7,463 Added 1.74%
437,275 $12.4 Million
Q1 2023

May 11, 2023

BUY
$21.74 - $30.93 $804 - $1,144
37 Added 0.01%
429,812 $9.87 Million
Q4 2022

Feb 13, 2023

BUY
$24.81 - $31.52 $228,549 - $290,362
9,212 Added 2.19%
429,775 $12.1 Million
Q3 2022

Nov 14, 2022

BUY
$19.51 - $34.14 $565,341 - $989,274
28,977 Added 7.4%
420,563 $11.9 Million
Q2 2022

Aug 15, 2022

SELL
$17.06 - $31.42 $62,473 - $115,060
-3,662 Reduced 0.93%
391,586 $8.68 Million
Q1 2022

May 13, 2022

BUY
$26.68 - $34.81 $256,474 - $334,628
9,613 Added 2.49%
395,248 $11.5 Million
Q4 2021

Feb 11, 2022

SELL
$29.58 - $49.78 $738,494 - $1.24 Million
-24,966 Reduced 6.08%
385,635 $12.7 Million
Q3 2021

Nov 16, 2021

BUY
$41.92 - $58.18 $1.47 Million - $2.04 Million
35,095 Added 9.35%
410,601 $19 Million
Q2 2021

Aug 16, 2021

BUY
$52.06 - $61.27 $5.13 Million - $6.04 Million
98,579 Added 35.6%
375,506 $20.7 Million
Q1 2021

May 17, 2021

BUY
$44.23 - $57.5 $455,392 - $592,020
10,296 Added 3.86%
276,927 $14.3 Million
Q4 2020

Feb 16, 2021

BUY
$33.21 - $46.54 $111,784 - $156,653
3,366 Added 1.28%
266,631 $11.6 Million
Q3 2020

Nov 13, 2020

SELL
$33.87 - $55.93 $495,755 - $818,647
-14,637 Reduced 5.27%
263,265 $9.22 Million
Q2 2020

Aug 14, 2020

BUY
$34.45 - $53.48 $943,551 - $1.46 Million
27,389 Added 10.93%
277,902 $14.9 Million
Q1 2020

May 15, 2020

SELL
$31.52 - $53.81 $374,331 - $639,047
-11,876 Reduced 4.53%
250,513 $8.89 Million
Q4 2019

Feb 07, 2020

BUY
$30.08 - $50.59 $894,970 - $1.51 Million
29,753 Added 12.79%
262,389 $12.5 Million
Q3 2019

Nov 08, 2019

BUY
$32.4 - $49.58 $658,206 - $1.01 Million
20,315 Added 9.57%
232,636 $7.54 Million
Q2 2019

Aug 09, 2019

BUY
$46.17 - $68.1 $160,533 - $236,783
3,477 Added 1.66%
212,321 $10.6 Million
Q1 2019

May 14, 2019

BUY
$45.92 - $67.67 $1.15 Million - $1.7 Million
25,052 Added 13.63%
208,844 $14.1 Million
Q4 2018

Feb 14, 2019

BUY
$42.73 - $76.53 $45,336 - $81,198
1,061 Added 0.58%
183,792 $8.48 Million
Q3 2018

Nov 13, 2018

BUY
$71.67 - $91.95 $1.09 Million - $1.4 Million
15,228 Added 9.09%
182,731 $14.1 Million
Q2 2018

Aug 08, 2018

BUY
$73.22 - $99.55 $1.15 Million - $1.56 Million
15,691 Added 10.34%
167,503 $14.1 Million
Q1 2018

May 07, 2018

BUY
$59.83 - $86.53 $1.79 Million - $2.58 Million
29,837 Added 24.46%
151,812 $12.4 Million
Q4 2017

Jan 17, 2018

BUY
$52.12 - $72.33 $311,677 - $432,533
5,980 Added 5.16%
121,975 $6.97 Million
Q3 2017

Nov 13, 2017

BUY
$54.89 - $67.12 $6.37 Million - $7.79 Million
115,995
115,995 $7.74 Million

Others Institutions Holding AGIO

About AGIOS PHARMACEUTICALS, INC.


  • Ticker AGIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,818,000
  • Market Cap $1.94B
  • Description
  • Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...
More about AGIO
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.